본문 바로가기
HOME> 논문 > 논문 검색상세

학위논문 상세정보

진행성 비소세포 폐암 환자에서 젬사이타빈과 시스플라틴의 3주 주기 복합 항암 화학요법 원문보기
Three-week Scheduled Combination Chemotherapy of Gemcitabine and Cisplatin in advanced Non-small Cell Lung Cancer

  • 저자

    심기식

  • 학위수여기관

    慶尙大學校 大學院

  • 학위구분

    국내석사

  • 학과

    의학과

  • 지도교수

  • 발행년도

    2004

  • 총페이지

    iv, 37p.

  • 키워드

    비소세포폐암 폐암환자 젬사이타빈 시스플라틴 항암화학요법;

  • 언어

    kor

  • 원문 URL

    http://www.riss.kr/link?id=T10060315&outLink=K  

  • 초록

    Background: The combination chemotherapy of gemcitabine and cisplatin (GC) has proven effective in the treatment of advanced non-small cell lung cancer (NSCLC). However, the optimal schedule for administration of the two drugs has not yet been determined. I therefore started a phase Ⅱ trial to evaluate efficacy, toxicity and dose intensity (DI) for three-week scheduled chemotherapy of GC. Method: Between October 2000 and March 2003, a total of 56 patients with stage ⅢB and Ⅳ NSCLC enrolled in this study. Treatment schedule consisted of gemcitabine 1200mg/㎡ i.v. on day 1 and 8 and cisplatin 80 mg/㎡ i.v. on day 1 of each chemotherapy cycle followed by two weeks of rest. Results: Forty-eight patients were evaluable in resoponse and toxoicities in this study. The median DI was 529 mg/㎡/week for gemcitabine (66 %) and 22 mg/㎡/week for cisplatin (83%). Partial response were observed in 23 patients. The overall response rate was 47.8 % (95% CI, 33.6∼61.9%). Anemia and thrombocytopenia as the grade 3 to 4 toxicity were 8.3% and 8.3% respectively. The median survival time was 11.78 months (95% CI, 8.59∼14.97 months). No significant differences in response rate were observed according to sex, age, histology and DI of GC Conclusion: The 3-week scheduled combination chemotherapy of GC has a relatively high activity(overall response rate: 47.8%) with acceptable toxicities in patients with advanced NSCLC.


 활용도 분석

  • 상세보기

    amChart 영역
  • 원문보기

    amChart 영역